| Literature DB >> 33532303 |
Pu Li1, Chengming Wang1, Min Tang1, Peng Han1, Xiaoxin Meng1.
Abstract
BACKGROUND: This study aimed to evaluate the efficacy and safety of holmium laser enucleation of prostate (HoLEP) by using en-bloc and bladder neck preservation technique on benign prostatic hyperplasia (BPH) and assess the influence of this procedure on urinary and sexual functional outcomes.Entities:
Keywords: Holmium laser enucleation of prostate; bladder neck preservation; en-bloc; retrograde ejaculation; sexual function
Year: 2021 PMID: 33532303 PMCID: PMC7844485 DOI: 10.21037/tau-20-852
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Video 1Holmium laser enucleation of prostate (HoLEP) procedure by an en-bloc and bladder neck preservation technique.
Figure 1Holmium laser enucleation of prostate (HoLEP) procedure by an en-bloc and bladder neck preservation technique. (A) Image of verumontanum before operation. Initial resection was performed proximal to the verumontanum by using an inverted U-shaped incision. (B) An anatomic plane was formed between the surgical capsule and hyperplastic gland. The white and black arrows showed the surgical capsule and hyperplastic gland, respectively. (C) At 12 o’clock in the bladder neck. The hyperplastic gland was stripped from the bladder neck near 12 o’clock to cut into the bladder. Dense, whitish, ring-shaped internal sphincter tissue can be observed when hyperplastic gland was peeled off from the bladder neck. (D) The hyperplastic gland was continuously resected on either side from 12 o’clock, and the internal sphincter tissue of bladder neck was retained. The white and black arrows showed the bladder neck and hyperplastic gland, respectively. (E) A preserved bladder neck similar to a dam when observed from the six o’clock position. (F) A preserved verumontanum which was completely preserved to retain normal ejaculation. (G) An integrated external sphincter. The bladder neck and prostatic cavity can be observed at the external sphincter. (H) Image of cystoscopy at 3 months after surgery as observed at the verumontanum.
Baseline characteristics and perioperative variables for study participants
| Variable | Mean ± SD or no. of patients (%) |
|---|---|
| Number of cases (n) | 704 |
| Preoperative | |
| Age (year) | 67.8±6.9 |
| Prostate volume (mL) | 70.5±15.4 |
| Total PSA (ng/mL) | 3.2±2.6 |
| Perioperative | |
| Operation time (min) | 69.3±14.8 |
| EBL (mL) | 62.1±23.7 |
| Resected prostate weight (g) | 53.4±17.6 |
| Blood transfusion (n) | 0 (0%) |
| TURS (n) | 0 (0%) |
| Duration of catheterisation (days) | 2.1±1.5 |
| Hospital stay (days) | 5.4±3.6 |
SD, standard deviation; PSA, prostate specific antigen; EBL, estimated blood loss; TURS, transurethral resection syndrome.
Pre- and postoperative urinary function results
| Variable | Preoperation | 3 months | 6 months | 12 months |
|---|---|---|---|---|
| IPSS (score) | 21.8±4.5 | 6.6±2.0* | 5.8±1.4* | 5.5±2.2* |
| QoL (score) | 5.1±0.8 | 2.4±0.7* | 2.2±0.8* | 2.3±0.6* |
| PVR (mL) | 92.3±83.9 | 22.5±15.6* | 25.7±16.8* | 21.4±12.4* |
| Qmax (mL/s) | 5.7±2.4 | 19.2±3.7* | 20.3±2.4* | 20.6±3.8* |
| Incontinence (n, %) | ||||
| Mild | – | 38, 5.4% | 12, 1.6% | 4, 0.6% |
| Moderate | – | 3, 0.4% | 0, 0 | 0, 0 |
| Severe | – | 0, 0 | 0, 0 | 0, 0 |
IPSS, international prostatic symptomatic score; QoL, quality of life; PVR, post-void residual volume; and Qmax, maximum urinary flow rate. *, t-Test, compared with preoperative variables, P<0.05.
Pre- and postoperative sexual functional results
| Variable | Preoperation | 6 months | 12 months | P value | |
|---|---|---|---|---|---|
| 6 months | 12 months | ||||
| Erectile function | |||||
| IIEF-5 | 17.02±3.75 | 17.33±2.04 | 17.34±3.39 | 0.67 | 0.75 |
| EHGS | 3.03±0.62 | 3.06±0.52 | 3.02±0.44 | 0.74 | 0.86 |
| Ejaculation function | |||||
| Ejaculation pain (n, %) | 0 | 0 | 0 | – | – |
| Retrograde ejaculation (n, %) | 0 | 25 (11.7%) | 25 (11.7%) | – | – |
| Semen volume | |||||
| Increase (n, %) | / | 0 (0%) | 0 (0%) | – | – |
| Decrease (n, %) | / | 82 (43.6%) | 82 (43.6%) | – | – |
| Constant (n, %) | / | 106 (56.4%) | 106 (56.4%) | – | – |
IIEF-5, five-item version of the International Index of Erectile Function; EHGS, Erection Hardness Grading Scale.